source
- Wall Street reacts negatively to AstraZeneca-Bristol Myers merger talks, shares tumbleA report in the Financial Times, followed by Reuters, said AstraZeneca and Bristol Myers Squibb have been discussing a possible combination in recent months. The news triggered a sharp sell-off. A…
- Curium to acquire Lantheus in $8 billion deal, offering $102.5 per share with upside potentialCurium announced it will purchase radiopharmaceutical company Lantheus in a transaction valued at about $8 billion. The agreement sets the purchase price at $102.5 for each Lantheus share, and inc…